1-pentyl-1H-indole-3-carbonyl chloride | 1338925-23-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 1-pentyl-1H-indole-3-carbonyl chloride
• 英文别名: 1-pentylindole-3-carbonyl chloride
• CAS: 1338925-23-7
• 化学式: C₁₄H₁₆ClNO
• 分子量: 249.74
• InChiKey: TYPHVVHLLMOKCC-UHFFFAOYSA-N

物化性质

• 沸点：
  374.4±15.0 °C(Predicted)
• 密度：
  1.14±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  17
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-pentyl-1H-indole-3-carbonyl chloride 、 苯胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 14.0h， 以81%的产率得到1-pentyl-N-phenyl-1H-indole-3-carboxamide
  参考文献：
  名称：

  The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse

  摘要：

  Two novel adamantane derivatives, adamantan-1-yl (1-pentyl-1H-indo1-3-yl) methano ne (AB-001) and N-(adamtan-1-yl)-1-pentyl-1H-indole-3-carboxamide (SDB-001), were recently identified as cannabimimetic indoles of abuse. Conflicting anecdotal reports of the psychoactivity of AB-001 in humans, and a complete dearth of information about the bioactivity of SDB-001, prompted the preparation of AB-001, SDB-001, and several analogues intended to explore preliminary structure-activity relationships within this class. This study sought to elucidate which structural features of AB-001, SDB-001, and their analogues govern the cannabimimetic potency of these chemotypes in vitro and in vivo. All compounds showed similar full agonist profiles at CB1 (EC50 = 16-43 nM) and CB2 (EC50 = 29-216 nM) receptors in vitro using a FLIPR membrane potential assay, with the exception of SDB-002, which demonstrated partial agonist activity at CB2 receptors. The activity of AB-001, AB-002, and SDB-001 in rats was compared to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and cannabimimetic indole JWH-018 using biotelemetry. SDB-001 dose-dependently induced hypothermia and reduced heart rate (maximal dose 10 mg/kg) with potency comparable to that of Delta(9)-tetrahydrocannabinol (Delta(9)-THC, maximal dose 10 mg/kg), and lower than that of JWH-018 (maximal dose 3 mg/kg). Additionally, the changes in body temperature and heart rate affected by SDB-001 are of longer duration than those of Delta(9)-THC or JWH-018, suggesting a different pharmacokinetic profile. In contrast, AB-001, and its homologue, AB-002, did not produce significant hypothermic and bradycardic effects, even at relatively higher doses (up to 30 mg/kg), indicating greatly reduced potency compared to Delta(9)-THC, JWH-018, and SDB-001.

  DOI：

  10.1021/cn400035r
• 作为产物：
  描述：

  1-戊基-1H-吲哚-3-羧酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 生成 1-pentyl-1H-indole-3-carbonyl chloride
  参考文献：
  名称：

  探索与SDB-006、5F-SDB-006，CUMYL-PICA和5F-CUMYL-PICA相关的合成大麻素的大麻素受体的立体化学和构象性要求

  摘要：

  合成大麻素受体激动剂（SCRA）代表了发展最快的一类新型精神活性物质（NPS）。尽管最近手性吲哚-3-羧酰胺SCRA的流行和效力，有关这些NPS对人CB1和CB2受体的对映体偏倚的药理学数据很少。制备了一系列衍生自（S）-和（R）-α-甲基苄基胺并具有1-烷基取代基变异特征的同手性吲哚-3-羧酰胺，对其进行了药理学评价，并将其与衍生自枯基和苄基胺的相关非手性同类物进行比较。竞争性结合测定表明，所有类似物均来自α-甲基苄胺的对映体（14 –17）显示CB1（K i = 47.9–813 nM）和CB2（K i = 47.9–347 nM）的亲和力处于相应苄基的中间值（10 – 13，CB1 K i = 550 nM到> 10μM ; CB2 ķ我= 61.7 nM至>10μM）和枯基衍生物（6 - 9，CB1 ķ我= 12.6-21.4纳米; CB2 ķ我= 2.95-24.5纳米）。在荧光

  DOI：

  10.1021/acschemneuro.0c00591

文献信息

• Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure–activity relationships, physicochemical properties and biological activity
  作者：Antoni R. Blaazer、Jos H.M. Lange、Martina A.W. van der Neut、Arie Mulder、Femke S. den Boon、Taco R. Werkman、Chris G. Kruse、Wytse J. Wadman

  DOI：10.1016/j.ejmech.2011.08.021

  日期：2011.10

  efforts, several high affinity CB1/CB2 dual cannabinoid receptor ligands were identified. Indole-3-carboxamide 17 displayed single-digit nanomolar affinity and ∼80 fold selectivity for CB1 over the CB2 receptor. The azaindoles displayed substantially improved physicochemical properties (lipophilicity; aqueous solubility). Azaindole 21 elicited potent cannabinoid activity. Cannabinoid receptor agonists 17

  报告了一系列新型的大麻素1（CB 1）和大麻素2（CB 2）受体配体的发现，合成和构效关系（SAR）。基于所述aminoalkylindole类大麻素受体激动剂，联苯部分被引入作为新颖的亲脂性的吲哚3-酰基取代基在11 - 16。此外，系绳是与羧酰胺接头取代-3-羰基17 - 20和氮杂吲哚（吡咯并吡啶）核被设计为具有改进的物理化学性质的吲哚生物电子等排在21 - 25。通过这些SAR努力，几个高亲和力CB 1 / CB 2确定了双重大麻素受体配体。吲哚-3-羧酰胺17对CB 1比CB 2受体具有几位数的纳摩尔亲和力和约80倍的选择性。氮杂吲哚显示出显着改善的理化性质（亲脂性；水溶性）。氮杂吲哚21引起有效的大麻素活性。大麻素受体激动剂17和21在大麻素受体调节的神经传递的急性大鼠脑切片模型中有效地调节了兴奋性突触传递。